aTyr Pharma shares rose by 9.1% during pre-market trading after the company announced the FDA's agreement on the phase 3 study protocol for efzofitimod – the company's leading candidate – in patients with chronic symptomatic pulmonary sarcoidosis with restrictive lung disease.
The announcement was published via GlobeNewswire. The company expects to commence activities in the fourth quarter of 2026 and plans to submit applications in the U.S. and Europe. The study is global, randomized, double-blind, placebo-controlled; the primary endpoint is forced vital capacity (FVC). The design is based on a subgroup analysis from the phase 3 EFZO-FIT study: patients with restrictive lung disease receiving a dose of 5.0 mg/kg showed clinically significant improvements in FVC and several patient-reported outcomes compared to placebo. Data will be presented at the WASOG 2026 congress.
Against the backdrop of overall pressure on U.S. markets (S&P 500 -0.6%, Dow Jones -0.4%, NASDAQ -1.1%), the rise in shares is particularly notable. The consensus among analysts remains at 'Buy' – despite a challenging period that included restructuring and staff reductions earlier this year. The FDA agreement eliminates a key source of uncertainty following earlier EFZO-FIT results, provides investors with clearer timelines, and strengthens the company's strategy around efzofitimod in the field of interstitial lung diseases.
Related articles
